NEWS AND EVENTS
GO BACK
InterVenn’s GlycoVision platform featured in ESMO 2024 oral presentation: Novel Serum Glycoproteomic Biomarkers Predict Response to Nivolumab plus Cabozantinib Versus Sunitinib in Advanced RCC: Analysis from CheckMate 9ER
October 1, 2024
